Healthcare Facilities company Narayana Hrudayalaya announced Q2FY25 results Consolidated total operating revenue was Rs 14,000 million for Q2FY25 as compared to Rs 13,052 million in Q2FY24, reflecting a growth of +7.3 % YoY and +4.4% QoQ. Consolidated EBITDA stood at Rs 3,320 million, reflecting a margin of 23.7% as against Rs 3,265 million in Q2 FY24, translating into a growth of +1.7% YoY and +1.4% QoQ. Consolidated PAT stood at Rs 1,988 million, reflecting a margin of 14.2% as compared to Rs 2,267 million in Q2 FY24, translating into a change of -12.3% YoY and -1.3% QoQ. India operating revenue was Rs 11,684 million for Q2FY25 as compared to Rs 10,527 million in Q2FY24, reflecting a growth of +11.0% YoY and +7.6% QoQ. Cayman operating revenue was Rs 2,423 million for Q2FY25 as compared to Rs 2,607 million in Q2FY24, reflecting a change of -7.0% YoY and -9.4% QoQ. As of Q2FY25, the Total Borrowings less Cash & Bank Balance and Current Investments was Rs 2,684 million, representing a net debt to equity ratio of 0.08. Emmanuel Rupert, Managing Director and Group CEO, Narayana Hrudayalaya Limited, said: “The second quarter of the fiscal year has delivered strong performance after a robust start to the year. We are pleased to report the highest-ever revenue on a quarterly basis with sustainable profitability margins, which is on account of improvement in realizations and increased domestic patient footfalls. Despite the slowdown in international patient inflows due to geopolitical tensions in the neighborhood, we have been able to show overall growth in revenues during the quarter through our enhanced focus on domestic business. The performance improvement is seen across our flagship units, and other hospitals, and steady improvements in the performance of our newer hospitals. There is a decline in the HCCI revenue and margins for the quarter on account of the steps we have undertaken to optimize the operations between the existing and the new hospitals, and the costs in the new hospital being incurred upfront, which we believe is transitory and should normalize over the next few quarters. NHIC has delivered another strong quarter of increased patient transactions and revenue growth. We remain on track to deliver on our expectations for the full fiscal year for all our businesses including the new ventures." Result PDF